FOR LABORATORY RESEARCH USE ONLY INDIA-WIDE ENQUIRY SUPPORT

COMPOUND RESEARCH GUIDE

CJC-1295 No DAC in India: Research Guide, Evidence & Legal Status

CJC-1295 No DAC is discussed widely online, often with more certainty than the evidence supports. This India-focused guide separates laboratory interest from demonstrated clinical outcomes.

Published by The Peptide Co.Updated

What researchers examine

CJC-1295 No DAC is studied in GHRH-receptor, peptide-kinetics and endocrine-signalling models. The relevance of a result depends on material identity, model, comparator, endpoint and study design.

Laboratory and animal findings can identify mechanisms worth studying, but they do not by themselves establish safety or effectiveness in people.

How to read the evidence

Search for CJC-1295 No DAC in PubMed and ClinicalTrials.gov, then identify whether each record is preclinical, observational or interventional. Check sample size, methods, endpoints, conflicts and publication status.

A mechanism, anecdote or registered trial is not regulatory approval. Evidence can also differ by formulation, manufacturer and jurisdiction.

India catalogue context

The linked CJC-1295 No DAC product record shows the current laboratory presentation, INR catalogue price, research status and India-wide enquiry route.

It does not provide personal-use, dosage, administration, treatment or medical advice.

Legal status in India

CJC-1295 No DAC is not an approved medicine in India as far as we are aware. It is listed as a laboratory research material only, not for human consumption. Check current CDSCO guidance or consult a legal professional for your own use case.

Our guide to the legal status of research peptides in India explains the difference between research materials and approved medicines.

Material identity before a literature comparison

Keep No DAC / modified GRF 1-29 separate from long-acting DAC-linked CJC-1295. The source table identifies the long-acting study explicitly.

For each source, record the model, comparator, endpoint and relevant limitations. The papers below are selected starting points, not a systematic review or a test of our batches.

Before a laboratory procurement enquiry

Match the product record to the required presentation and request available batch documentation privately before payment. Compare the report identity, method and result with the actual material offered.

Use the catalogue for current prices and availability; the article update date is not a batch-test date.

Frequently asked questions.

What is CJC-1295 No DAC?

CJC-1295 No DAC is a research compound studied in GHRH-receptor, peptide-kinetics and endocrine-signalling models. It is listed by The Peptide Co. as a laboratory research material only.

Is CJC-1295 No DAC legal in India?

CJC-1295 No DAC is not an approved medicine in India as far as we are aware. It is supplied as a research-use-only laboratory material. This is general information, not legal advice; check current CDSCO guidance.

Where can I buy CJC-1295 No DAC in India?

The Peptide Co. lists CJC-1295 No DAC with INR prices on its product page and ships from Bengaluru across India. Standard delivery is ₹150 (3–5 days), express ₹350 (2–3 days) and cash on delivery ₹150 extra.

Selected studies and source context.

Curated starting points, not a systematic review, comparative ranking or batch-test record. Follow the source for the full methods and results.

Material, study model, measured topic and source limitations
SourceStudy modelMeasured topic and limitations
Long-acting CJC-1295 endocrine study ↗Teichman et al. · 2006 · PMID 16352683Two randomised placebo-controlled studies in healthy adults

Measures pharmacokinetics, growth hormone and IGF-I over 28- and 49-day study periods.

This is long-acting CJC-1295 evidence. Do not reuse its duration or pharmacokinetics as measurements for a No DAC / modified GRF 1-29 product.